Page last updated: 2024-09-04

varespladib and Inflammation

varespladib has been researched along with Inflammation in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (60.00)	29.6817
2010's	1 (20.00)	24.3611
2020's	1 (20.00)	2.80

Authors

Authors	Studies
Barvaliya, M; Biradar, P; Dodakallanavar, J; Harish, DR; Hiremath, K; Mahadevamurthy, RK; Patil, VS; Roy, S; Sampat, GH	1
Kokotos, G; Kokotou, MG; Limnios, D; Nikolaou, A; Psarra, A	1
Garcia-Garcia, HM; Serruys, PW	1
Gelb, MH; Rosenson, RS	1
Abraham, E; Bandi, V; Dmitrienko, A; Farid, N; Forgue, ST; Gervich, D; Jiang, F; Lowry, SF; Macias, W; Naum, C; Schein, RM; Skerjanec, S; Wunderink, R	1

Reviews

4 review(s) available for varespladib and Inflammation

Article	Year
Unraveling snake venom phospholipase A Pharmacological reports : PR, 2023, Volume: 75, Issue:6 Topics: Acetates; Animals; Horses; Humans; Inflammation; Phospholipases A2; Sheep; Snake Bites; Snake Venoms	2023
Inhibitors of phospholipase A Expert opinion on therapeutic patents, 2017, Volume: 27, Issue:2 Topics: Acetates; Animals; Benzaldehydes; Biomarkers; Cardiovascular Diseases; Drug Design; Humans; Indoles; Inflammation; Keto Acids; Oximes; Patents as Topic; Phospholipase A2 Inhibitors	2017
Phospholipase A2 inhibitors. Current opinion in lipidology, 2009, Volume: 20, Issue:4 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acetates; Animals; Atherosclerosis; Benzaldehydes; Blood Proteins; Humans; Indoles; Inflammation; Keto Acids; Oximes	2009
Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes. Current cardiology reports, 2009, Volume: 11, Issue:6 Topics: Acetates; Animals; Arteriosclerosis; Disease Progression; Humans; Indoles; Inflammation; Keto Acids; Lipoproteins; Mice; Oxidative Stress; Phospholipases A2, Secretory; Phospholipids	2009

Trials

1 trial(s) available for varespladib and Inflammation

Article	Year
Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Critical care medicine, 2003, Volume: 31, Issue:3 Topics: Acetates; Aged; Cause of Death; Critical Illness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Female; Group II Phospholipases A2; Hospital Mortality; Humans; Indoles; Inflammation; Infusions, Intravenous; Keto Acids; Male; Middle Aged; Molecular Weight; Multiple Organ Failure; Phospholipases A; Phospholipases A2; Proportional Hazards Models; Prospective Studies; Safety; Survival Analysis; Systemic Inflammatory Response Syndrome; Time Factors; Treatment Outcome; United States	2003

Article

Year

Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.

Critical care medicine, 2003, Volume: 31, Issue:3

Topics: Acetates; Aged; Cause of Death; Critical Illness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Female; Group II Phospholipases A2; Hospital Mortality; Humans; Indoles; Inflammation; Infusions, Intravenous; Keto Acids; Male; Middle Aged; Molecular Weight; Multiple Organ Failure; Phospholipases A; Phospholipases A2; Proportional Hazards Models; Prospective Studies; Safety; Survival Analysis; Systemic Inflammatory Response Syndrome; Time Factors; Treatment Outcome; United States

2003